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The application of modern high-throughput genomics to the study of cancer genomes has exploded in the past few
years, yielding unanticipated insights into the myriad and complex combinations of genomic alterations that lead to the
development of cancers. Coincident with these genomic approaches have been computational analyses that are capable
of multiplex evaluations of genomic data toward specific therapeutic end points. One such approach is called “immuno-
genomics” and is now being developed to interpret protein-altering changes in cancer cells in the context of predicted
preferential binding of these altered peptides by the patient’s immune molecules, specifically human leukocyte antigen
(HLA) class I and II proteins. One goal of immunogenomics is to identify those cancer-specific alterations that are likely
to elicit an immune response that is highly specific to the patient’s cancer cells following stimulation by a personalized
vaccine. The elements of such an approach are outlined herein and constitute an emerging therapeutic option for cancer
patients.
Cancer immunologists developed experimentally
testable hypotheses around the idea that mutated pro-
teins in cancer cells provided favored targets for
immune response in the mid-1980s (De Plaen et al.
1988; Monach et al. 1995). Their hypotheses were in-
spired by earlier observations of immune-capable mice
that developed spontaneous cancers and, after removal
and rechallenge, exhibited resistance to their original
cancers (Foley 1953; Prehn and Main 1957; Old
1982). This implied that cancer-specific immunity was
a plausible resistance mechanism, but the mechanism
for immunity was unclear. Experimental approaches to
test for the presence of tumor-specific mutant antigens
or “neoantigens” were aided by discoveries in immunol-
ogy that elucidated the role and functions of the human
leukocyte antigen (HLA) proteins (Bjorkman et al.
1987; Babbitt et al. 2005), and by the advent of molec-
ular cloning techniques. This combination led to the
cloning and identification of the first tumor neoantigen
by Boon and colleagues, a peptide called MAGE-A1
that was derived from a melanoma patient sample (van
der Bruggen et al. 1991). As exciting as this proof of
hypothesis was at the time, the laborious and lengthy
procedures required to identify a single tumor-specific
neoantigen that was highly unique to the patient’s
disease meant there was no clear trajectory for this ap-
proach in a clinical setting.
IMMUNOGENOMICS AND NEOANTIGEN
PREDICTION
Several recent developments have made it more plau-
sible to revisit the notion of identifying tumor-unique
neoantigenic peptides, however. In particular, the devel-
opment and widespread use of next-generation sequenc-
ing (NGS) platforms has figured prominently in this trend
(Mardis 2017). Introduced in the mid-2000s, these instru-
ments and their accompanying techniques led to the first
cancer whole-genome sequencing study that compared a
tumor with normal genome for a single patient, establish-
ing that somatic mutations could be discovered in the
comparison (Ley et al. 2008). Selective hybridization-
based techniques known as “hybrid capture” emerged
in 2009 and permitted isolation and sequencing of only
the known protein-coding exons from a whole-genome
library (the exome). This “whole-exome sequencing”
approach significantly simplified data analysis for the
identification of DNA-level changes that were somatic
(i.e., specific to the tumor cells) and led to changes in
the amino acid sequences of the resulting proteins. The
foundational underpinning for mutation discovery lies in
the reference human genome sequence, which serves as a
template for NGS read alignment. Over time, the increas-
ing length of NGS reads, the advent of read-pair data
(both ends of each library fragment are sequenced), and
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the improved mapping algorithms have led to overall im-
provements in the quality of NGS read alignment on the
highly repetitive and complex human genome reference.
Beyond these advances, the most important step in this
process—namely, the proper identification of variants in
aligned NGS read data—has also improved over time.
There are various algorithmic approaches to somatic
variant identification from NGS data that typically are
highly tuned to the type of variant being detected. The
basic workflow involves detecting variants in the aligned
read data from the tumor sample, and separately in the
normal sample, and then comparing the variants at
each locus to eliminate those shared between tumor
and normal from further consideration because they are
constitutional or “germline” in origin (Ding et al. 2010).
In practice, each variant identification algorithm has
strengths and weaknesses (Griffith et al. 2015), and there-
fore most data analysis approaches to somatic variant
identification use more than one variant caller and con-
sider most strongly the shared or consensus variant lists
called by each algorithm as likely true positives. Further-
more, variant detection accuracy is a function of data
coverage, so most variant detection approaches utilize a
pre- or post-variant call filtering scheme to remove all
variants identified at loci with suboptimal coverage
depth. Generally speaking, detection of somatic single-
nucleotide variants (SNVs) or point mutations is the most
straightforward variant type to identify. Detecting the
insertion or deletion (indel) of one or more nucleotides
is more difficult, as gapped alignment or assembly of the
sequence read data that define the indel is required. Here,
some proportion of the indel-containing reads will not
map without special alignment algorithms, because of
the need to produce a gapped alignment with sufficient
length of sequence similarity to anchor the read accurate-
ly to the surrounding sequence. As a result, coverage
is almost always lower at indel variant sites because of
read mapping difficulties. Finally, structural variants are
the most difficult to detect with high accuracy. These
variants include chromosomal-scale events such as inver-
sions, translocations, and deletions and are detected
based on mismapped read-pair data following NGS read
alignment. Both indels and structural variants, when they
occur in protein-coding genes, can provide important and
potentially immunogenic changes to the amino acid se-
quences of expressed proteins in a cancer cell.
The next step is annotating the variants that have been
identified, by interpreting their altered nucleotide se-
quences in the context of their protein-coding impact.
This is straightforward in SNVs, but indels that result in
a shift in the open reading frame (frameshift) and gene-
fusing structural variants are more difficult to interpret
properly. Automated annotation software such as Variant
Effect Predictor (VEP) (McLaren et al. 2016) or ANNO-
VAR (Wang et al. 2010) typically is used for variant
interpretation. For many genes in the human genome,
multiple transcripts have been identified, which compli-
cates the annotation process because one must specify
which transcript is to be annotated. In the absence of
adequate RNA-seq data to infer the correct transcript,
one typically annotates from the transcript with the high-
est evidence for expression. Tissue-specific expression
data sets, such as GTEx (www.gtexportal.org/), also
can be consulted for transcript information, if desired.
Once the variants and their proper notation are deter-
mined along with their flanking sequences, the results
are parsed for use in the neoantigen detection schema
described below. Typically for major histocompatibility
complex (MHC) class I restricted neoantigen discovery,
we tile through the variant-containing region of each pro-
tein with peptides of eight to 11 amino acids to generate
the test sequences for neoantigen evaluation. For MHC
class II restricted neoantigen discovery, the tiled peptides
are 15 amino acids in length.
Stringent alignment of NGS reads from the normal tis-
sue comparator onto the HLA coding genes permits the
haplotype of each patient to be determined from NGS
exome data. There are several approaches to HLA typing
from NGS data, including HLAminer (Warren et al.
2012), OptiType (Szolek et al. 2014), and ATHLATES
(Liu et al. 2013). HLAminer and OptiType also can call
HLA haplotypes from RNA-seq data. In high-mutation-
load tumor types, it also is advised to evaluate and anno-
tate the HLA gene sequences from the tumor tissue NGS
data, because there may be inactivating (nonsense or
frameshift) mutations in one or more of these genes that
would preclude further consideration of these mutation-
inactivated HLA proteins in neoantigen prediction.
The final step in neoantigen discovery is the prediction
of binding affinities for each novel somatic mutation-
translated set of peptides to the patient’s HLA proteins.
The development of modeling algorithms that calculate
HLA binding affinities has been an active area of research
that has resulted in several approaches such as analysis by
neural network-based algorithms that are trained on mea-
sured binding affinities (e.g., NetMHC), scattering-ma-
trix method (SMM)-based approaches, and others (Peters
and Sette 2005; Lundegaard et al. 2008; Srivastava et al.
2013). The large number of algorithms indicates the at-
tendant difficulty of identifying neoantigens, although
precision has improved over time, especially for class I
HLA proteins, for which more experimental data exist,
even for the more rare haplotypes. Class II neoantigen
binding is more difficult to predict because of the nature
of the peptide binding site, which is open at both ends,
permitting the flanking amino acids around the nine-ami-
no-acid-core binding motif to influence binding affinity
in a context-dependent manner (Paul et al. 2015).
Because of the complexities of the aforementioned set
of steps required to generate predicted neoantigens, our
group published a computational pipeline called pVAC-
Seq (personalized Variant Antigens by Cancer Sequenc-
ing) that is designed to perform these steps in sequence
(Hundal et al. 2016). pVAC-Seq requires several input
data, including an annotated list of somatic variants,
comparison sequences from the native peptide correlates,
predicted HLA class I haplotypes for the patient, and
RNA-seq-derived data regarding mutant expression lev-
els for each of the input peptides. The overall workflow
for neoantigen prediction is represented in Figure 1.
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Neoantigen prediction can be used clinically to achieve
several therapeutic goals, depending on the nature of the
study. Two case reports are presented to illustrate the
clinical utility of neoantigen prediction to (1) predict neo-
antigen load as a consequence of an identified mismatch
repair gene defect and as an indicator of likely response to
checkpoint blockade therapy, (2) identify changes in
a temporal series of tumors from the same individual
patient, and (3) design a personalized vaccine for a patient
with recurrent cancer.
CASE REPORTS
We recently reported (Johanns et al. 2016) on an indi-
vidual case of a male patient (early 30s) with a history of
colon polyps who presented with a brain tumor that was
removed by craniotomy and diagnosed as a glioblastoma
multiforme (GBM), World Health Organization (WHO)
grade IV with primitive neuroectodermal tumor (PNET)
features. Following resection, the patient received radia-
tion and temozolomide (TMZ) treatment per standard
of care, but new symptoms subsequent to this treatment
during high-dose maintenance TMZ led to the laminec-
tomy and diagnosis by histopathology of a drop spinal
metastasis. Intermediate to the primary and secondary
diagnoses, a panel gene test (Foundation One) identified
an abnormally elevated mutation rate, and a reflex assay
of blood DNA for germline susceptibility identified
a known pathogenic mutation in polymerase epsilon
(POLE L424 V). Based on this result, the patient received
a PD-1 checkpoint blockade therapy (pembrolizumab)
for about 3 wk following the removal of the drop metas-
tasis. Upon experiencing further complications after 3 wk
of pembrolizumab therapy, the patient was subsequently
diagnosed with a second drop metastasis lower on the
spinal cord. This tumor alsowas resected by laminectomy
and diagnosed as a GBM with PNET features by histo-
pathology. Since all three occurrences of this patient’s
cancer were banked, we isolated DNA and RNA from
each sample. An exome capture-based sequencing com-
parison of all three tumors to a matched blood normal
from the patient coupled with RNA-seq from each of
the three tumors were used to characterize the patient’s
changes in tumor heterogeneity and neoantigen load over
time. We also performed immunohistochemistry (IHC)
on slides from each tumor resection sample to identify
whether the use of checkpoint blockade therapy had in-
fluenced the tumor infiltration of different immune mol-
ecules behind the blood–brain barrier.
As demonstrated in our retrospective sequencing and
analysis, genomic characterization of a tumor series can
Figure 1. Generalized workflow diagram for identification of tumor-specific mutant antigens (“neoantigens”) from next-generation
sequencing (NGS) data. MHC, major histocompatibility complex; TCR, T-cell receptor.
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verify an anticipated “hyper” mutation rate for patients
with a POLE pathogenic mutation and can illustrate
response to treatment in the form of dramatic changes
in tumor heterogeneity and subclonal tumor cell popula-
tions. This was especially evident in the comparison of
the first drop metastasis to the second, with an anti PD-1
therapy intermediate (Fig. 2). Similarly, we utilized our
genomic data to identify significant flux in the neoanti-
gens identified in all three tumors. Our comparative
analysis of RNA expression data obtained from each
tumor illustrated the significant changes in immune cell
infiltrates following anti-PD1 checkpoint blockade ther-
apy, and these were supported by IHC studies that further
illustrated the significant influx of immune cells follow-
ing anti-PD1 therapy (Fig. 3). Importantly, this study
provided the first combined genomic and molecular evi-
dence that checkpoint blockade could influence immune
activity behind the blood–brain barrier in a central ner-
vous system (CNS) tumor.
We also have used immunogenomic methods to iden-
tify neoantigens in individual patient cancers for the
purposes of designing a personalized vaccine-based ther-
apeutic (Carreno et al. 2015). This work built upon proof-
of-concept studies completed with Robert Schreiber’s
laboratory using carcinogen-induced sarcoma mouse
models with a high mutational load. These studies inves-
tigated whether the combination of exome sequencing
and RNA sequencing could identify neoantigens in this
tumor model (Matsushita et al. 2012) and further evalu-
ated whether a peptide vaccine based on the identified
neoantigens could be used to vaccinate the mouse and
lead to the eradication of the tumor (Gubin et al. 2014).
In the human vaccine trial, the pVAC-Seq pipeline (Hun-
dal et al. 2016) identified neoantigens from melanoma
samples in three patients with BRAF-mutated melanomas
that had received prior treatment with a BRAF small-
molecule-inhibitor therapy and with an anti-CTLA4
checkpoint blockade therapy (ipilimumab). After identi-
fying neoantigens, the vaccines were produced by isolat-
ing dendritic cells from each patient and culturing them
to maturity based on established in vitro methods, and
then coupling the mature dendritic cells with synthetic
peptides for each unique neoantigen plus two control
peptides (based on gp-100 shared antigens). These den-
Figure 2. Comparison of tumor heterogeneity and subclonal population variation in sequential samples from a single patient.
(Reprinted, with permission, from Johanns et al. 2016,# AACR.)
Figure 3. Immunohistochemistry-based evaluation of sequential glioblastoma multiforme (GBM) samples for immune infiltration
before and after anti PD-1 therapy. (Reprinted, with permission, from Johanns et al. 2016,# AACR.)
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dritic cell cultures were infused into the patients in a
series of three vaccine infusions at 2-wk intervals. The
overall workflow is shown in Figure 4.
Postvaccination, we then monitored each patient’s
response using flow cytometry–based dextramer assays
designed to specifically identify which of the neoantigens
were eliciting a specific CD8þ T-cell response. In each
case, we saw strong responses from three of the seven
neoantigens utilized per patient (each set of neoantigens
is completely unique to each patient), and we saw strong
responses from our control gp-100 peptides. To further
investigate the T-cell response, we evaluated the com-
plexity of the T-cell receptor (TCR) repertoire using the
Adaptive Biosciences immunoSEQ assay (http://www
.adaptivebiotech.com/immunoseq), which also uses next-
generation sequencing to provide the TCR data for anal-
ysis. Our results demonstrated that, for neoantigens with
a discernable response by dextramer-flow cytometry
assay, the corresponding T cells showed increased diver-
sity in the TCR repertoire post-vaccine compared with
pre-vaccine.
These initial studies have led to new clinical trials
of personalized vaccines in tumor types with a lower
average mutational load than UV-associated melanomas,
such as triple-negative breast cancer. Here, the challenge
is to identify a sufficient number of neoantigens using the
pVAC-Seq pipeline, for the purposes of designing the
vaccine. To address this, we have been expanding
the types of variants considered in our analysis beyond
SNVs (point mutations). For example, although they are
less frequent and more difficult to identify precisely, in-
sertion or deletion (indel) variants can shift the open
reading frame of a protein, thereby creating a novel tu-
mor-unique peptide that may be a neoantigen. Similarly,
the identification of structural variants that generate fu-
sion proteins can also potentially encode a neoantigenic
peptide at the junction sequence of the two proteins. We
recently used an approach to mine fusion transcripts from
cancer RNA-seq data for purposes of evaluating neoanti-
genicity of predicted fusions. The implementation of
this approach, called INTEGRATE-Neo, was tested in
the context of TCGA prostate cancer data (exome and
RNA-seq) for a common fusion peptide created by the
translocation that fuses TMPRSS2 to ERG in 50% of
prostate cancers. As shown in Figure 5, the HLA binding
energy calculated for this novel fusion peptide varies
across patients according to HLA haplotype. Like class
I neoantigens, we also wish to evaluate class II restricted
neoantigens and add these to our vaccines. We are active-
ly pursuing these and other changes to our neoantigen
discovery pipeline (https://github.com/griffithlab/
pVAC-Seq).
Finally, we would like to expand our personalized neo-
antigen vaccine approaches to tumor types with signifi-
cantly lower mutational burden, such as pediatric cancers.
In particular, the opportunity to pursue these studies lies
in patients emerging with recurrent disease, post-stan-
dard-of-care therapies such as radiation and alkylating
chemotherapies like TMZ. In a study published by Cost-
ello’s laboratory, 30% of pediatric glioma patients with
recurrent tumors post-radiation and TMZ demonstrated a
significant elevation in their tumor mutational burden
posttherapy (van Thuijl et al. 2015). These children might
represent reasonable subjects for a clinical trial to evalu-
ate a personalized neoantigen vaccine in the recurrent
setting. In this regard, since the TMZ-induced mutations
are subclonal (i.e., not in the founder clone), we would
need to include a combination of founder clone variants
from the primary tumor and newer, TMZ-induced sub-




Although these new applications of genomics to clin-
ical cancer diagnostics and therapeutics are exciting and
Figure 4. Overall workflow for creating a dendritic cell (DC) vaccine based on mis-sense somatic point mutations (single-nucleotide
variants [SNVs]) that generate putative neoantigens.
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potentially transformational, we have many remaining
questions to answer. Examples include questions about
the optimal number and types of neoantigens that are
ideal for vaccine efficacy, the type of vaccine platform
(dendritic cell–based, peptide-based, DNA-based, and
so on) that is scalable, rapid to produce, and affordable
so that many patients can benefit (if indeed, benefit is
demonstrated). Better information about how patients re-
spond to a vaccine across the spectrum of tumor burden is
needed, so we can more effectively design our clinical
trials. For example, are patients with advanced tumor
burden less likely to have a clinical response or benefit
because the immune system, although activated by the
vaccine, cannot respond fast enough to eradicate their
cancers? Conversely, do patients require some minimal
level of tumor burden to achieve a benefit by giving the T
cells elicited by the vaccine a target to attack? And final-
ly, with a tumor burden eliminated by surgery, will the
immune surveillance remain? Or will surveillance poten-
tially be eluded by the emergence of new tumors that
have suppressed the expression of the neoantigens target-
ed by the vaccine? Since this phenomenon of neoepitope
editing already has been demonstrated in acquired resis-
tance to checkpoint blockade therapies (Anagnostou
et al. 2016), it is likely also in the therapeutic vaccine
setting.
CONCLUSION
The evolving applications of modern genomics and
computational analysis to the immunology-based study
of cancer have transformed our studies since these central
concepts of cancer immunology were hypothesized in
the 1980s. Certainly, the facility with which somatic
mutations can be identified in individual tumor samples
has encouraged progress, but vital contributions were
required toward the algorithmic evaluation of mutant
peptides in the context of each patient’s HLA haplotypes
and in devising novel immunotherapeutics. Immunoge-
nomics has been demonstrated to be clinically informa-
tive in several early studies, outlined here, and in research
that builds the case for clinical translation. As our level of
sophistication increases in identifying neoantigens across
the spectrum of mutation types and HLA classes, foun-
dational knowledge about cancer immunology will result
as will our understanding of how best to apply this infor-
mation to clinical care.
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